Company | Name | Exchange | Sector | Industry | 3 Month | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shanghai Allist Pharmaceuticals Co | Shanghai | Healthcare | Biotechnology & Medical Research | 26.9% | CN¥3.17KCr | 19.8x | 0.14 | CN¥65.85 | -6.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.4% Upside | Upgrade to Pro+ | |
Jiangsu Asieris Pharmaceuticals | Shanghai | Healthcare | Biotechnology & Medical Research | 7.3% | CN¥378Cr | -9x | 0.55 | CN¥6.61 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.8% Upside | Upgrade to Pro+ | |
Dongxing Securities | Shanghai | Financial | Investment Banking & Investment Services | 4.5% | CN¥3.52KCr | 27.1x | 0.14 | CN¥10.91 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -22.3% Downside | Upgrade to Pro+ | |
Beigene | Shanghai | Healthcare | Biotechnology & Medical Research | 1.1% | CN¥1.30KCr | -0.3x | -1.67 | CN¥189.78 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15% Upside | Upgrade to Pro+ | |
Sichuan Biokin Pharmaceutical | Shanghai | Healthcare | Pharmaceuticals | -1% | CN¥7.84KCr | 21.3x | 0.03 | CN¥193.71 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.3% Upside | Upgrade to Pro+ | |
Ruida | Shenzhen | Financial | Investment Banking & Investment Services | -2.2% | CN¥628Cr | 20.1x | 0.42 | CN¥13.98 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -16.3% Downside | Upgrade to Pro+ | |
Dizal Jiangsu Pharmaceutical | Shanghai | Healthcare | Biotechnology & Medical Research | -4.2% | CN¥1.76KCr | -20.2x | -0.98 | CN¥41.19 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.5% Upside | Upgrade to Pro+ | |
Chongqing Genrix Biopharmaceutical | Shanghai | Healthcare | Pharmaceuticals | -6.9% | CN¥928Cr | -11.8x | -1.35 | CN¥24.83 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Holly Futures | Shenzhen | Financial | Investment Banking & Investment Services | -9.1% | CN¥252Cr | 109.1x | 1.43 | CN¥9.92 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
RemeGen | Shanghai | Healthcare | Biotechnology & Medical Research | -17.2% | CN¥1.19KCr | -5.5x | 0.43 | CN¥27.80 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.3% Upside | Upgrade to Pro+ | |
Innovita Biological Tech | Shanghai | Healthcare | Healthcare Equipment & Supplies | -22.2% | CN¥452Cr | 14.9x | 0.08 | CN¥32.84 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shandong Cvicse Middleware | Shanghai | Technology | Software & IT Services | -22.5% | CN¥246Cr | 32.8x | 0.56 | CN¥28.82 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mabwell Shanghai Bioscience | Shanghai | Healthcare | Biotechnology & Medical Research | -29.4% | CN¥691Cr | -6.4x | 0.5 | CN¥15.81 | -8.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |